PNC-27

Classification: Experimental Anti-Cancer Peptide, p53-Derived HDM-2 Binding Peptide Sequence: 32 amino acids (p53 residues 12-26 + penetratin leader sequence) Full Sequence: H-Pro-Pro-Leu-Ser-Gln-Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Val-Lys-Val-Gln-Arg-Gly-OH Molecular Weight: 4,031.72 Da FDA Status: NOT APPROVED Legal Status: ILLEGAL to market for cancer treatment in the United States

Executive Summary

PNC-27 is a synthetic 32-amino-acid peptide derived from the tumor suppressor protein p53, designed to selectively kill cancer cells by binding to HDM-2 (human double minute 2) protein expressed on cancer cell membranes. The peptide consists of residues 12-26 from the HDM-2-binding domain of p53 fused to a cell-penetrating peptide (penetratin) sequence that facilitates membrane insertion.

Proposed Mechanism: PNC-27 purportedly binds to HDM-2 proteins abnormally expressed on the plasma membranes of cancer cells (but not normal cells), inducing transmembrane pore formation (35-40 nm inner diameter, 80-90 nm outer diameter) that causes rapid necrotic cell death within 4 hours. The peptide also disrupts mitochondrial membranes, providing a dual cytotoxic mechanism. Selectivity is based on the observation that cancer cells aberrantly express HDM-2 on their surface, while normal cells do not.

Preclinical Evidence: In vitro studies demonstrate selective toxicity to multiple cancer cell lines (breast, lung, pancreatic, ovarian, leukemia) at concentrations of 150-500 µg/mL, with 90-92% growth inhibition. Animal studies show tumor regression without overt toxicity to normal tissues. Ex vivo studies on patient-derived ovarian cancer cells confirmed efficacy. However, ZERO human clinical trials have been conducted.

Human Safety Concerns: A case report described massive gastrointestinal hemorrhage in a patient who received experimental PNC-27 therapy at a clinic in Mexico. While causation is uncertain, the temporal relationship raises serious safety concerns. No published Phase 1 safety trials exist.

Pharmacokinetics: Presumed very short half-life (<1 hour) due to protease susceptibility. No human PK data. Animal studies used continuous infusion pumps (Alzet pumps) or daily injections. Oral bioavailability likely zero; routes explored include IV, intratumoral, nebulized, and suppository formulations.

Current Status: PNC-27 is available from online "research chemical" suppliers and marketed by some international clinics (primarily Mexico) as experimental cancer therapy. Use in humans is illegal and unsafe per FDA. No legitimate clinical trials are recruiting. The peptide remains a purely experimental compound with insufficient safety and efficacy data for human use.

Core Peptides Availability: NOT AVAILABLE (WebFetch returned image data; no product listing)

Goal Relevance:

• Seeking alternative cancer treatments when conventional therapies have failed
• Exploring experimental options for targeting specific cancer cell types
• Interested in cutting-edge research for selective cancer cell destruction
• Looking for non-traditional therapies for aggressive cancer forms
• Considering novel compounds for potential cancer treatment breakthroughs

Chemical Structure & Composition

Primary Structure

Full Amino Acid Sequence (32 residues):

H-Pro-Pro-Leu-Ser-Gln-Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Val-Lys-Val-Gln-Arg-Gly-OH

Functional Domains:

1. p53-Derived HDM-2 Binding Domain (Residues 12-26):

   • Sequence: PPLSQETFSDLWKLL
   • Corresponds to residues 12-26 of wild-type p53 tumor suppressor protein
   • This region normally binds HDM-2 in the nucleus to regulate p53 activity
   • Contains critical binding residues Phe19, Trp23, Leu26

2. Penetratin Leader Sequence:

   • Cell-penetrating peptide (CPP) derived from Antennapedia homeodomain protein
   • Facilitates membrane insertion and cellular uptake
   • Provides amphipathic character enabling transmembrane pore formation

Physicochemical Properties

• Molecular Formula: C₁₈₈H₂₉₃N₅₃O₄₄S
• Molecular Weight: 4,031.72 Da
• Net Charge (pH 7.4): Highly positive (multiple Lys, Arg residues)
• Solubility: Water-soluble; typically formulated in aqueous buffers
• Hydrophobicity: Contains hydrophobic residues (Pro, Leu, Trp, Phe) enabling membrane interaction
• Stability: Susceptible to proteolytic degradation by serum proteases (short half-life in vivo)

Synthesis

• Method: Solid-phase peptide synthesis (SPPS) using Fmoc chemistry
• Purification: Reverse-phase HPLC
• Purity: Research-grade products claim ≥95% purity

Structural Biology

HDM-2 Binding Conformation:

• PNC-27 adopts an α-helical structure when bound to HDM-2 (residues 1-109)
• Binding affinity similar to native p53 peptide (Kd ~100-500 nM estimated)
• Crystal structure studies (PNAS 2010) confirmed p53-like binding mode
• Forms 1:1 complex with HDM-2, followed by dimerization to create transmembrane pores

References:

• Anticancer peptide PNC-27 adopts an HDM-2-binding conformation - PMC
• PNC-27 Peptide - ProSpec
• PNC-27 | MedChemExpress

Mechanism of Action

1. Selective HDM-2 Membrane Binding (Primary Mechanism)

HDM-2 Expression in Cancer vs. Normal Cells:

• Normal Cells: HDM-2 protein is located in the nucleus, where it regulates p53 tumor suppressor by promoting its degradation
• Cancer Cells: Aberrantly express HDM-2 on the plasma membrane surface (mechanism unclear; possibly due to oncogenic transformation, ER stress, or altered trafficking)
• Key Finding: Membrane HDM-2 is present in breast, lung, pancreatic, ovarian, and leukemia cancer cells but absent in untransformed cell lines (MCF-10-2A, normal hematopoietic cells)

Experimental Proof of Selectivity:

• Transfection Study: When normal MCF-10-2A cells were transfected to express full-length HDM-2 on their surface, they became susceptible to PNC-27-induced lysis
• Conclusion: Membrane HDM-2 expression is the sole determinant of PNC-27 selectivity

Binding Mechanism:

1. Recognition: PNC-27 binds to the p53-binding pocket of membrane-bound HDM-2 (residues 1-109)
2. Complex Formation: Forms 1:1 PNC-27:HDM-2 complex in a temperature-independent step
3. Dimerization: Two PNC-27:HDM-2 complexes dimerize in a highly temperature-dependent step
4. Pore Formation: Dimers insert into membrane and oligomerize to form transmembrane pores

2. Transmembrane Pore Formation & Necrosis

Pore Characteristics (Electron Microscopy):

• Inner Diameter: 35-40 nm
• Outer Diameter: 80-90 nm
• Structure: Toroidal pores with lipid headgroups lining the inner surface
• Kinetics: Pore formation occurs within minutes; cell lysis within 2-4 hours

Necrotic Cell Death (Not Apoptosis):

• Rapid membrane permeabilization → loss of ionic gradients
• Cellular swelling and organelle rupture
• Release of intracellular contents (DAMPs - damage-associated molecular patterns)
• NO caspase activation or DNA laddering (hallmarks of apoptosis absent)
• Advantage: Necrosis bypasses apoptotic resistance mechanisms (e.g., Bcl-2 overexpression, caspase deficiency)

3. Mitochondrial Membrane Disruption (Secondary Mechanism)

Intracellular Effects:

• PNC-27 enters cancer cells via penetratin-mediated uptake
• Binds to mitochondrial membranes, causing:
  • Mitochondrial outer membrane permeabilization (MOMP)
  • Cytochrome c release
  • Loss of mitochondrial membrane potential (Δψm)
  • ATP depletion

Dual Targeting:

• Simultaneous plasma membrane and mitochondrial disruption ensures rapid, irreversible cell death
• Even cells with defective plasma membrane repair mechanisms cannot escape

4. Cancer Selectivity: Why Normal Cells Are Spared

HDM-2 Membrane Expression:

• Cancer cells: High membrane HDM-2 (mechanism: oncogenic stress, p53 mutations drive HDM-2 overexpression and mislocalization)
• Normal cells: HDM-2 restricted to nucleus; minimal/no membrane expression

Experimental Evidence:

• Normal hematopoietic cells: No cytotoxicity at concentrations up to 500 µg/mL
• Normal mammary epithelial cells (MCF-10-2A): Resistant unless transfected with membrane HDM-2
• Mice toxicity studies: No weight loss, normal organ histology despite tumor regression

Critical Question (Unresolved): Why do cancer cells express HDM-2 on membranes? Hypotheses include:

1. ER stress → misfolding → surface trafficking
2. Oncogenic signaling disrupts normal compartmentalization
3. p53 mutations → HDM-2 overexpression → saturation of nuclear localization machinery

5. Efficacy Across Cancer Types

Demonstrated Susceptibility (In Vitro/Ex Vivo):

Tumor Regression (Animal Models):

• Mice with xenografted breast tumors: significant tumor shrinkage with daily PNC-27 injections
• No toxic effects on normal tissues (liver, kidney, bone marrow histology normal)

Summary Table: Mechanisms

References:

• Anti-Cancer Peptide PNC-27 Kills Cancer Cells - PubMed
• Anticancer peptide PNC-27 adopts HDM-2-binding conformation - PNAS
• Targeting Membrane HDM-2 by PNC-27 - Anticancer Research
• Ex vivo Efficacy in Ovarian Cancer - Ann Clin Lab Sci

Pharmacokinetics

CRITICAL LIMITATION: NO Human Pharmacokinetic Data

NO published human PK studies exist. All information below is extrapolated from in vitro stability assays and limited animal studies.

Absorption & Bioavailability

Oral Administration:

• Bioavailability: Presumed ZERO
• Reasons: 32-amino-acid peptide rapidly degraded by GI proteases; poor intestinal permeability
• Conclusion: Oral route not viable

Intravenous (IV):

• Bioavailability: 100% by definition
• Animal Use: Continuous IV infusion via Alzet osmotic pumps (implanted subcutaneously in mice)
• Dosing: 2 mg/day continuous infusion in mice (maximum tolerated dose)

Intratumoral Injection:

• Animal Studies: Direct injection into xenografted tumors
• Advantage: High local concentration; reduced systemic exposure
• Limitation: Not applicable to metastatic or inaccessible tumors

Nebulized Inhalation:

• Formulation: Aerosolized solution for lung cancer

Suppository Formulations:

• Routes: Rectal, vaginal
• Indication: Colorectal or gynecologic cancers
• Evidence: Anecdotal only; no published studies

Distribution

Volume of Distribution:

• Unknown
• Expected to be limited to extracellular fluid (4 kDa peptide; does not cross membranes without penetratin-mediated uptake)

Tissue Distribution:

• Tumor Uptake: Enhanced by penetratin sequence and HDM-2 binding
• Normal Tissues: Minimal uptake due to lack of membrane HDM-2 (theoretical)
• No Biodistribution Studies: Published data absent

Metabolism

Proteolytic Degradation (Primary Route):

• "Little or no resistance to cleavage by serum proteases in vivo"
• Enzymes: Aminopeptidases, carboxypeptidases, endopeptidases
• Metabolites: Degraded to constituent amino acids (non-toxic)

Half-Life:

• Estimate: "Presumed short half-life" (<1 hour)
• Evidence: Repeated daily dosing required in animal studies to maintain efficacy
• Membrane-Bound Form: Once bound to HDM-2, peptide lifetime increases (protected from proteases)

Excretion

Renal Clearance:

• Low MW (4 kDa) < glomerular filtration cutoff (~60 kDa)
• Rapidly filtered by kidneys and excreted in urine
• Renal Impairment: Dose adjustment may be needed (theoretical; no data)

Dosing Implications

Animal Studies:

• MTD (Mouse): 2 mg/day IP or continuous IV infusion
• Human Equivalent Dose (HED): ~0.16 mg/kg/day (for 70 kg person: ~11 mg/day)
• CRITICAL: This is speculative extrapolation; NO human dose-finding studies exist

In Vitro Concentrations:

• Effective Range: 150-500 µg/mL for 90-92% cancer cell kill
• Challenge: Achieving systemic concentrations of 150-500 µg/mL in humans would require massive IV doses (grams), likely toxic

Clinical Reality:

• Underground clinics reportedly use IV infusions of unknown doses

Comparative PK: Therapeutic Peptides

Key Difference: Approved peptides have robust PK/PD studies, optimized formulations, and proven safety/efficacy.

References:

• Evaluation of therapeutic peptides for cancer - PMC
• What is PNC-27 - Peptide Sciences

Dosing Protocols

Preclinical Research Dosing

In Vitro (Cell Culture):

• Concentration Range: 10-500 µg/mL
• Effective Dose: 150-300 µg/mL for most cancer cell lines (90% growth inhibition)
• Incubation Time: 24-72 hours with daily re-dosing (due to short peptide half-life)

Animal Studies (Mice):

• Intraperitoneal (IP) Bolus: 2 mg/day (maximum tolerated dose)
• Continuous IV Infusion: 2 mg/day via Alzet pump (implanted subcutaneously)
• Intratumoral Injection: Variable doses; direct tumor injection
• Duration: 10-21 days
• Outcome: Tumor regression without overt toxicity

Human Equivalent Dose (HED) Calculation:

• Mouse 2 mg/day ÷ 12.3 (conversion factor) = 0.16 mg/kg/day
• For 70 kg person: ~11 mg/day (THEORETICAL; NOT VALIDATED)

Anecdotal "Clinical" Protocols (UNVERIFIED)

Underground Clinic Reports (Mexico, International):

• Route: IV infusion
• Dose: 10-50 mg per infusion (highly variable; no standardization)
• Frequency: 2-3 times per week
• Duration: 4-12 weeks

Nebulized Inhalation (Lung Cancer Claims):

• Dose: Unknown concentration
• Frequency: Daily inhalation

Suppository Formulations:

• Route: Rectal or vaginal
• Indication: Colorectal, cervical, ovarian cancers
• Dose: Unknown
• Evidence: None

FDA-Approved Alternatives (Evidence-Based Cancer Therapies)

Instead of experimental PNC-27, patients should pursue FDA-approved therapies:

References:

• Ex vivo Efficacy in Ovarian Cancer - Ann Clin Lab Sci
• FDA warns cancer patients not to use PNC-27 - FDA

Clinical Research & Evidence

CRITICAL LIMITATION: ZERO Human Clinical Trials

NO Phase 1, 2, or 3 clinical trials of PNC-27 have been published or registered on ClinicalTrials.gov. All evidence is preclinical only.

Preclinical Studies

Study 1: Discovery & Mechanism (PNAS 2010 - PMC2836618)

• Title: "Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes"
• Key Findings:
  • PNC-27 binds HDM-2 with similar affinity to native p53 peptide
  • Forms transmembrane pores (35-40 nm inner diameter)
  • Kills breast (MCF-7), lung (A549), pancreatic (PANC-1) cancer cells at 150-300 µg/mL
  • NO toxicity to normal mammary epithelial cells (MCF-10-2A)
• Significance: Proof-of-concept for cancer selectivity
• Limitation: In vitro only

Study 2: Leukemia Cell Necrosis (Ann Clin Lab Sci 2014 - PMID 25117093)

• Title: "The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line"
• Model: HL-60 leukemia cells
• Key Findings:
  • Necrosis in 4 hours at 150-300 µg/mL
  • Membrane HDM-2 expression confirmed by immunofluorescence
  • NO toxicity to normal hematopoietic cells
• Significance: Demonstrates efficacy in blood cancers (not just solid tumors)

Study 3: Patient-Derived Ovarian Cancer (Ann Clin Lab Sci 2015 - PMID 26663795)

• Title: "Ex vivo Efficacy of Anti-Cancer Drug PNC-27 in the Treatment of Patient-Derived Epithelial Ovarian Cancer"
• Model: Primary ovarian cancer cells from surgical specimens (N=3 patients)
• Key Findings:
  • 90-92% growth inhibition at concentrations >200 µg/mL
  • Efficacy in chemotherapy-resistant samples
  • Confirmed membrane HDM-2 expression in patient tumors
• Significance: First evidence in human-derived cancer cells (not immortalized cell lines)
• Limitation: Ex vivo only; does not address in vivo PK, toxicity, or efficacy

Study 4: Mitochondrial Disruption (PubMed 38802154 - 2024)

• Title: "Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes"
• Key Findings:
  • Dual mechanism: plasma membrane pores + mitochondrial membrane disruption
  • Cytochrome c release from mitochondria
  • Necrosis pathway confirmed (no caspase activation)

Study 5: Animal Efficacy (Multiple Studies)

• Tumor Models: Breast, lung, pancreatic xenografts in nude mice
• Dosing: 2 mg/day IP or continuous IV infusion
• Outcomes:
  • Tumor regression in 60-80% of treated mice
  • No weight loss or organ toxicity (histology normal)
  • Prolonged survival vs. untreated controls
• Limitation: Xenograft models; immunocompromised mice; unclear translation to humans

Human "Evidence" (Case Reports - NOT Clinical Trials)

Case Report: Massive GI Hemorrhage (ACG Journal 2017)

• Title: "Experimental PNC-27 Therapy and Massive GI Hemorrhage"
• Patient: Cancer patient who received PNC-27 at Mexican clinic
• Outcome: Presented with massive gastrointestinal bleeding requiring transfusions
• Temporal Relationship: Bleeding occurred during/after PNC-27 treatment course
• Causation: Difficult to prove, but raises serious safety concern
• Conclusion: First documented adverse event possibly linked to PNC-27

No Other Published Human Data:

• Anecdotal claims of efficacy from international clinics lack documentation
• No peer-reviewed case series, retrospective studies, or prospective trials

Evidence Gaps

NO Data On:

• Phase 1 safety (maximum tolerated dose, dose-limiting toxicities)
• Phase 2 efficacy (tumor response rates, progression-free survival)
• Phase 3 comparative trials (vs. standard of care)
• Optimal dosing, route, schedule
• Drug interactions
• Long-term safety
• Pharmacokinetics in humans
• Biomarkers predicting response (beyond HDM-2 expression)

Evidence Quality Assessment

Overall Evidence Grade for Human Use: GROSSLY INSUFFICIENT

References:

• Anticancer peptide PNC-27 - PNAS
• PNC-27 induces leukemia cell necrosis - Ann Clin Lab Sci
• Ex vivo Efficacy in Ovarian Cancer - Ann Clin Lab Sci
• Experimental PNC-27 Therapy and GI Hemorrhage - ACG

Safety Profile

Preclinical Safety (Animal Studies)

Acute Toxicity (Mice):

• Maximum Tolerated Dose (MTD): 2 mg/day IP or IV
• NO weight loss, lethargy, or behavioral changes at MTD
• Organ Histology: Liver, kidney, bone marrow, GI tract all normal

Chronic Toxicity:

• Mice treated for 21 days continuous at MTD "thrived" and exhibited weights similar to untreated controls

Selectivity Confirmation:

• Normal lymphocytes: NO cytotoxicity at concentrations toxic to cancer cells
• Normal epithelial cells: Resistant unless transfected with membrane HDM-2

Conclusion: Preclinical safety data suggest good therapeutic index in animals. However, animal safety does not guarantee human safety (e.g., TGN1412 cytokine storm disaster).

Human Adverse Events

Case Report: Massive GI Hemorrhage

• Patient: Cancer patient treated with experimental PNC-27 at Mexican clinic
• Event: Massive gastrointestinal bleeding requiring hospitalization and blood transfusions
• Timing: During or shortly after PNC-27 treatment course
• Outcome: Patient survived after transfusions
• Causality: Possible but unproven; temporal relationship suggestive

Proposed Mechanism (Speculative):

• PNC-27 might have caused necrosis of GI tract tumor deposits, leading to vessel erosion and bleeding
• Alternatively, off-target toxicity to GI epithelium (if low-level membrane HDM-2 present)

FDA Adverse Event Reports:

• FDA stated: "However, the agency has not received reports of illnesses or serious adverse events related to PNC-27" (as of October 2016)
• Limitation: Voluntary reporting; actual AE incidence unknown

Theoretical Safety Concerns

1. Immunogenicity:

• PNC-27 contains non-human penetratin sequence (from Drosophila)
• Risk of anti-drug antibodies (ADAs) with repeat dosing
• ADAs could cause hypersensitivity reactions or neutralize activity

2. Off-Target Toxicity:

• If normal tissues express trace membrane HDM-2, PNC-27 could cause toxicity
• GI tract, hematopoietic stem cells, reproductive organs particularly vulnerable

3. Tumor Lysis Syndrome:

• Rapid necrosis of large tumor burden → release of intracellular contents
• Risk of hyperkalemia, hyperphosphatemia, acute kidney injury
• Standard TLS prophylaxis (allopurinol, hydration) may be required

4. Unknown Long-Term Effects:

• Chronic necrotic cell death → inflammatory milieu
• Potential for fibrosis, organ dysfunction

Contraindications (Theoretical)

If Hypothetically Approved:

• Active infection (contamination risk)
• Severe bleeding disorder
• Large tumor burden near critical structures (risk of catastrophic necrosis/bleeding)

Comparison to Approved Cancer Therapies

Key Difference: Approved therapies have undergone rigorous safety testing with known AE profiles and mitigation strategies.

FDA Recommendations

For Patients:

• DO NOT use PNC-27 products
• Discuss FDA-approved treatment options with oncologist
• Report adverse events to FDA MedWatch (1-800-FDA-1088)

For Healthcare Providers:

• Counsel patients against using unapproved cancer therapies
• Report suspected PNC-27 use and adverse events to FDA

References:

• FDA warns cancer patients not to use PNC-27 - FDA
• FDA Issues Warning About PNC-27 - Cancer Therapy Advisor
• Experimental PNC-27 Therapy and GI Hemorrhage - ACG

Storage & Stability

Lyophilized Powder:

• Store at -20°C to -80°C
• Protect from light and moisture
• Shelf life: Unknown (no GMP manufacturing data)

Reconstituted Solution:

• Store at 2-8°C
• Use within 7 days (typical for peptides in solution)

Quality Concerns:

• No FDA-approved manufacturing; quality control unknown
• Third-party COAs unreliable

1. FDA warns cancer patients not to use PNC-27 - FDA
2. Anticancer peptide PNC-27 - PNAS
3. Anticancer peptide PNC-27 - PMC2836618
4. PNC-27 induces leukemia cell necrosis - PubMed
5. Ex vivo Efficacy in Ovarian Cancer - PubMed
6. Anti-Cancer Peptide PNC-27 - PubMed
7. Targeting Membrane HDM-2 - Anticancer Research
8. Experimental PNC-27 Therapy and GI Hemorrhage - ACG
9. What is PNC-27 - Peptide Sciences
10. Evaluation of therapeutic peptides - PMC

Document Version: 1.0 Last Updated: December 2024 Classification: EXPERIMENTAL - NOT APPROVED